Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial
The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to answer is that if it is possible to achieve the same long-term survival with and without the dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will underwent laparoscopic rectal radical resection with or without the dissection of the No.253 lymph node.
• Patient age between 18-75 years.
• Colonic biopsy pathology confirms adenocarcinoma.
• The inferior margin of the primary tumor is ≤ 7 cm from the anal verge, as confirmed by colonoscopy and baseline imaging at initial diagnosis.
• At initial treatment, imaging diagnoses the tumor T stage as less than or equal to 3.
• At initial treatment, imaging diagnoses no enlarged lymph nodes at the root of the inferior mesenteric artery.
• At initial treatment, imaging diagnoses the number of mesenteric metastatic lymph nodes as less than or equal to three.
• Strong willingness for surgery and signed informed consent.